参麦注射液联合综合心理干预在非小细胞肺癌化疗中的应用价值

The Role of Shenmai Injection Combined with Psychotherapy in Chemotherapy of Non-small Cell Lung Cancer

[目的]观察参麦注射液(SMI)联合综合心理干预在晚期非小细胞肺癌(NSCLC)化疗中的使用价值。[方法]晚期NSCLC79例,治疗组40例,采用常规化疗配合参麦注射液联合综合心理干预,并与单纯化疗的39例作对照,观察两组的体力状况、疗效、1年生存率、骨髓抑制情况等。[结果]治疗组和对照组的Karnofsky评分提高+稳定率为75.0%及46.2%、疗效稳定以上率(CR+PR+NC)为70.0%及46.2%,1年生存率为47.5%及25.6%。治疗组与对照组的Ⅱ度以上的白细胞下降的发生率分别为32.5%及53.8%(P=0.032),Ⅱ度以上的血小板下降的发生率分别为30.0%及46.2%(P=0.032),之间的差异均有统计学意义。[结论]治疗组的Karnofsky评分、疗效稳定以上率、1年生存率、骨髓抑制发生率均优于对照组,提示SMI及心理干预联合化疗治疗晚期NSCLC有增效减毒作用。

[Objective]To evaluate the efficacy of Shenmai injection combined with psychotherapy in chemotherapy of non-small cell lung cancer. [Method]79 cases of advanced non-small cell lung cancer were randomly divided into two groups,40 cases in observation group with Shenmai injection combined with chemotherapy and psychotherapy, 39 cases in control group with chemotherapy alone. The Karnofsky scores, therapeutic efficacy,one year survival rate and incidence of myelosuppression were evaluated. [Result] The two groups were significantly different in Karnofsky scores, therapeutic efficacy and one year survival rate. The improvement and stability rate of Karnofsky scores and that of therapeutic efficacy were 75.0 % and 70.0% in observation group, with 46.2% and 46.2% in control group,respectively. One year survival rate was 47.5% in observation group and 25.6% in control group,respectively. The incidence of myelosuppression had significant differences in the two groups, with grade 2-4 leucopenia 32.5% in observation group and 53.8% in control group （P=0.032）, with grade 2-3 thrombocytopenia 30.0% in observation group and 46.2% in control group（P=0.032）.[Conclusion] Combination treatment in observation group was superior to the treatment in control group,with a higher Karnofsky scores,more effective therapy,a higher one year survival rate and a lower incidence of myelosuppression. The treatment of Shenmai injection combind with chemotherapy could reduce toxicity and enhance therapeutic efficacy.